Table III.
Summary of telazorlimab PKs after dosing on days 1 and 85 during double-blind period (rich PK population)
| Telazorlimab dose (loading/maintenance) | Day 1 |
Day 85 |
||||
|---|---|---|---|---|---|---|
| Cmax (μg/mL) GM (CV) | Tmax (h), median (min-max) | AUC0-tau (h∙μg/mL) GM (CV) | CmaxSS (μg/mL) GM (CV) | TmaxSS (h) median (min-max) | AUC0-tauSS (h∙μg/mL) GM (CV) | |
| 1200 mg/600 mg q2w | 92.8 (12.3) | 119.9 (97.1-125.9) | 26,930∗ | 144.8 (6.8) | 109.1 (94.8-123.5) | 39,420 (2.6) |
| 600 mg/300 mg q2w | 47.0 (46.5) | 95.6 (24.1-120.0) | 12,170 (49.9) | 52.3 (45.8) | 95.6 (23.9-169.2) | 12,990 (40.3) |
| 600 mg/300 mg q4w | 50.0 (33.1) | 120.0 (94.5-169.3) | 20,340 (34.1) | 31.2 (60.4) | 115.6 (23.3-167.4) | 13,120 (49.5) |
| 150 mg/75 mg q4w | 16.6 (32.6) | 120.3 (24.0-168.7) | 6,671 (40.2) | 8.8 (73.6) | 119.2 (23.7-406.2) | 3,448 (97.8) |
CV, Coefficient of variation; GM, geometric mean; q2w, every 2 weeks; q4w, every 4 weeks.
∗
Not calculated because of missing data.